• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[与尿路感染患者分离出的大肠杆菌中磷霉素耐药性相关的生物学代价]

[Biological cost associated with fosfomycin resistance in Escherichia coli isolates from urinary tract infections].

作者信息

Alós J I, García-Peña P, Tamayo J

机构信息

Servicio de Microbiología, Hospital de Móstoles, Móstoles, Madrid. España.

出版信息

Rev Esp Quimioter. 2007 Jun;20(2):211-5.

PMID:17893758
Abstract

Resistance to fosfomycin develops rapidly in experimental conditions, although despite its frequent use in UTI, resistance in E. coli, the main uropathogen, is very low (1-3%), and has remained so for many years. The objective of this study was to ascertain whether E. coli fosfomycin-resistant strains have less fitness than those that are fosfomycin-sensitive in competing, and would therefore tend to disappear in their competition with fosfomycin-sensitive strains in the absence of antibiotics. Fosfomycin-resistant strains (n=11) with different phenotypes of resistance to other antibiotics were used. All but one were lactose (+). Fosfomycin-susceptible strains (n=15) that had the same phenotypes of resistance to other antibiotics as the resistant strains and which had the opposite pattern of lactose fermentation were also used. Thirty-three (33) competition experiments by pairs of strains were conducted in nutrient broth. Equal amounts of the strains were challenged (approx. 50% and approx. 50%) for 4 days, with a daily change to a new medium. Five differential counts were performed on days 0, 1, 2, 3 and 4. In 20 experiments (60.6%) there was a relative increase in the fosfomycin-sensitive strain. In 6 experiments (18.2%) there was a relative increase in the fosfomycin-resistant strain. In 7 experiments (21.2%), on the fourth day none of the strains reached 60%. When the data of the 26 (20+6) experiments in which there were changes were analyzed by the chi2 test there was a statistically significant difference (p=0.044). Resistance to fosfomycin could entail a biological cost (less fitness) for the majority of the E. coli strains assayed.

摘要

在实验条件下,对磷霉素的耐药性发展迅速,尽管其在治疗尿路感染中频繁使用,但主要尿路致病菌大肠杆菌的耐药率非常低(1%-3%),且多年来一直如此。本研究的目的是确定在竞争中,耐磷霉素的大肠杆菌菌株是否比磷霉素敏感菌株适应性更差,因此在无抗生素的情况下,与磷霉素敏感菌株竞争时是否会趋于消失。使用了对其他抗生素具有不同耐药表型的耐磷霉素菌株(n = 11)。除一株外,其余均为乳糖(+)。还使用了对其他抗生素具有与耐药菌株相同耐药表型且乳糖发酵模式相反的磷霉素敏感菌株(n = 15)。在营养肉汤中对菌株进行了33对竞争实验。将等量的菌株(约50%和约50%)接种,培养4天,每天更换新鲜培养基。在第0、1、2、3和4天进行了五次差异计数。在20次实验(60.6%)中,磷霉素敏感菌株相对增加。在6次实验(18.2%)中,耐磷霉素菌株相对增加。在7次实验(21.2%)中,第四天没有菌株达到60%。当用卡方检验分析有变化的26次(20 + 6)实验的数据时,存在统计学显著差异(p = 0.044)。对大多数检测的大肠杆菌菌株而言,对磷霉素的耐药性可能会带来生物学代价(适应性更差)。

相似文献

1
[Biological cost associated with fosfomycin resistance in Escherichia coli isolates from urinary tract infections].[与尿路感染患者分离出的大肠杆菌中磷霉素耐药性相关的生物学代价]
Rev Esp Quimioter. 2007 Jun;20(2):211-5.
2
CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin.产CTX-M-15的泌尿道大肠杆菌O25b-ST131-菌系B2已获得对磷霉素的耐药性。
J Antimicrob Chemother. 2009 Oct;64(4):712-7. doi: 10.1093/jac/dkp288. Epub 2009 Aug 11.
3
In vitro activity of fosfomycin against ciprofloxacin-resistant or extended-spectrum beta-lactamase-producing Escherichia coli isolated from urine and blood.磷霉素对从尿液和血液中分离出的耐环丙沙星或产超广谱β-内酰胺酶的大肠埃希菌的体外活性。
Diagn Microbiol Infect Dis. 2007 May;58(1):111-5. doi: 10.1016/j.diagmicrobio.2006.11.015. Epub 2007 Feb 14.
4
Mutators among CTX-M beta-lactamase-producing Escherichia coli and risk for the emergence of fosfomycin resistance.产CTX-Mβ-内酰胺酶的大肠埃希菌中的突变体与磷霉素耐药性出现的风险
J Antimicrob Chemother. 2006 Oct;58(4):848-52. doi: 10.1093/jac/dkl315. Epub 2006 Aug 5.
5
Biological cost of fosfomycin resistance in Escherichia coli in a murine model of urinary tract infection.尿路感 染 小鼠模型中大肠杆 菌对磷霉素耐药性的生物学代价。
Int J Med Microbiol. 2017 Dec;307(8):452-459. doi: 10.1016/j.ijmm.2017.09.019. Epub 2017 Sep 29.
6
In vitro activity of prulifloxacin against Escherichia coli isolated from urinary tract infections and the biological cost of prulifloxacin resistance.普卢利沙星对从尿路感染分离出的大肠杆菌的体外活性及普卢利沙星耐药的生物学代价。
Int J Antimicrob Agents. 2007 Jun;29(6):679-87. doi: 10.1016/j.ijantimicag.2007.01.009. Epub 2007 Mar 23.
7
Molecular mechanisms of fosfomycin resistance in clinical isolates of Escherichia coli.大肠杆菌临床分离株中磷霉素耐药的分子机制。
Int J Antimicrob Agents. 2010 Apr;35(4):333-7. doi: 10.1016/j.ijantimicag.2009.11.011. Epub 2010 Jan 13.
8
[Short communication: comparison of susceptibilities of Escherichia coli urinary tract isolates against fosfomycin tromethamine and different antibiotics].[简短通讯:大肠埃希菌尿路感染分离株对磷霉素氨丁三醇及不同抗生素的敏感性比较]
Mikrobiyol Bul. 2007 Jan;41(1):115-9.
9
Fosfomycin tromethamine as second agent for the treatment of acute, uncomplicated urinary tract infections in adult female patients in The Netherlands?在荷兰,磷霉素氨丁三醇作为成年女性患者急性单纯性尿路感染治疗的二线用药?
J Antimicrob Chemother. 2008 Aug;62(2):356-9. doi: 10.1093/jac/dkn177. Epub 2008 Apr 19.
10
[Antibiotic resistance rates of extended spectrum beta-lactamase producing Escherichia coli and Klebsiella spp. strains isolated from urinary tract infections in a private hospital].[从一家私立医院尿路感染患者中分离出的产超广谱β-内酰胺酶大肠埃希菌和克雷伯菌属菌株的抗生素耐药率]
Mikrobiyol Bul. 2008 Oct;42(4):713-5.

引用本文的文献

1
Emerging Concepts for the Treatment of Biofilm-Associated Bone and Joint Infections with IV Fosfomycin: A Literature Review.静脉注射磷霉素治疗生物膜相关骨与关节感染的新观念:文献综述
Microorganisms. 2025 Apr 23;13(5):963. doi: 10.3390/microorganisms13050963.
2
Activities of fosfomycin and rifampin on planktonic and adherent Enterococcus faecalis strains in an experimental foreign-body infection model.磷霉素和利福平在实验性异物感染模型中对浮游和黏附粪肠球菌菌株的活性
Antimicrob Agents Chemother. 2014;58(3):1284-93. doi: 10.1128/AAC.02583-12. Epub 2013 Oct 21.
3
Genomewide overexpression screen for fosfomycin resistance in Escherichia coli: MurA confers clinical resistance at low fitness cost.
全基因组过表达筛选大肠杆菌对磷霉素的耐药性:MurA 以低适应性成本赋予临床耐药性。
Antimicrob Agents Chemother. 2012 May;56(5):2767-9. doi: 10.1128/AAC.06122-11. Epub 2012 Feb 27.
4
Daptomycin, fosfomycin, or both for treatment of methicillin-resistant Staphylococcus aureus osteomyelitis in an experimental rat model.达托霉素、磷霉素或两者联合治疗实验性耐甲氧西林金黄色葡萄球菌骨髓炎。
Antimicrob Agents Chemother. 2011 Nov;55(11):4999-5003. doi: 10.1128/AAC.00584-11. Epub 2011 Aug 22.
5
Antimicrobial resistance in more than 100,000 Escherichia coli isolates according to culture site and patient age, gender, and location.根据培养部位和患者年龄、性别和地点,对 10 多万株大肠杆菌分离株的抗菌耐药性进行分析。
Antimicrob Agents Chemother. 2011 Mar;55(3):1222-8. doi: 10.1128/AAC.00765-10. Epub 2011 Jan 10.
6
Efficacy of fosfomycin in experimental osteomyelitis due to methicillin-resistant Staphylococcus aureus.磷霉素治疗耐甲氧西林金黄色葡萄球菌所致实验性骨髓炎的疗效。
Antimicrob Agents Chemother. 2011 Feb;55(2):931-3. doi: 10.1128/AAC.00881-10. Epub 2010 Nov 22.
7
Assessing the emergence of resistance: the absence of biological cost in vivo may compromise fosfomycin treatments for P. aeruginosa infections.评估耐药性的出现:体内缺乏生物学代价可能会影响铜绿假单胞菌感染的磷霉素治疗。
PLoS One. 2010 Apr 15;5(4):e10193. doi: 10.1371/journal.pone.0010193.